News

Childhood sleep disturbance linked to later psychosis


 

References

The presence of parasomnias such as nightmares, night terrors, and sleepwalking in childhood may be an early indicator of later psychotic experiences, report Dr. A. Thompson and coauthors in the division of mental health and well-being at the University of Warwick, Coventry, England.

In a study of 4,720 children in the United Kingdom, patients were evaluated via interview for sleep disturbances at age 12, and again for psychotic experiences at age 18. The presence of nightmares at age 12 was significantly associated with psychosis at age 18 (odds ratio = 1.62; 95% confidence interval, 1.19-2.20), the investigators reported.

Although nightmares and night terrors may have little significance for later psychopathology in many patients, parasomnias in those with additional risks such as a family psychiatric history or a past trauma may “have greater significance and may also highlight other unnoticed psychopathology or trauma,” Dr. Thompson and colleagues said in the report.

“Further work is needed to understand the mechanisms and interplay of risk factors, especially the role of trauma, in the relationship between these sleep disturbances and psychotic experiences,” the authors concluded.

The investigators reported no conflicts of interest.

Read the full study in the British Journal of Psychiatry.

Recommended Reading

Class of 2015: New drugs projected to earn billions and billions
MDedge Family Medicine
ICSR: Could a pediatric psychosis screen be on the horizon?
MDedge Family Medicine
FDA approves generic forms of aripiprazole
MDedge Family Medicine
AAN: Largest neuroleptic malignant syndrome study finds predictors of poor outcome
MDedge Family Medicine
Brexpiprazole is safe, effective for schizophrenia
MDedge Family Medicine
Legislation aims to improve treatment of serious mental illness
MDedge Family Medicine
ASCP: Moving from treatment to prevention in mental illness – an achievable goal?
MDedge Family Medicine
Antipsychotic prescriptions drop for children, but rise among teens, young adults
MDedge Family Medicine
Antipsychotic use down in children, up in adolescents and young adults
MDedge Family Medicine
FDA approves Rexulti for schizophrenia, depression in schizophrenia
MDedge Family Medicine